ONE-WAYDated event · through FY2027-H1
Acquisition of Worldwide Exclusive License to TMS-010 from Hokkaido University
A project to obtain worldwide exclusive development, manufacturing and commercialization rights to TMS-010, a drug candidate for spinal cord injury, from Hokkaido University, and to proceed with nonclinical evaluation and preparations for clinical trials.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2025-Q1 →Last written FY2027-H1
Directionhelps1 helps · 0 hurts · 0 flat